Business
Initial assessment of EpiSwitch assay in ALS trial
Initial assessment of EpiSwitch assay in ALS trial.
About this update from Oxford Biodynamics Plc
[{"type":"text","content":"\n \n \n \n \n \n \n \n \n Oxford BioDynamics Plc\n \n \n \n \n Massachusetts General Hospital reports results of Interim Analysis from REFINE-ALS biomarker trial by Mitsubishi Tanabe Pharma USA, utilizing Oxford Biodynamics' EpiSwitch® platform for prognostic stratification of fast progression ALS\n \n \n \n ·\n \n The multicenter REFINE-ALS prospective trial for Radicava® (Edaravone), sponsored by Mitsubishi Tanabe Pharma America (MTPA), has been\n \n \n conducted in collaboration with Massachusetts General Hospital\n \n \n and Harvard Medical School\n \n \n \n ·\n \n Dr. James Berry, Director of Massachusetts General Hospital (MGH) Neurological Clinical Research Institute (NCRI), shared the interim analysis from the REFINE-ALS prospective trial, including the initial assessment of the EpiSwitch assay\n \n \n \n ·\n \n In the subset of data, baseline EpiSwitch predicted slow versus fast progressors. The proportion of fast progressors predicted by EpiSwitch was higher in the REFINE ALS participants compared with the control population from the ANSWER ALS participants\n \n \n \n \n \n Oxford, UK - 16 December, 2022\n \n -\n Oxford BioDynamics, Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests for immune health based on the EpiSwitch® 3D genomics platform, announces the initial results from an interim analysis conducted for the REFINE-ALS prospective trial. The results from a subset of data, highlight the blood-based EpiSwitch prognostic stratification of patients with fast progressing Amyotrophic Lateral Sclerosis (ALS).\n The Phase 4 REFINE-ALS trial (\n \n NCT04259255\n \n )[1] is a prospective, multicenter study sponsored by Mitsubishi Tanabe Pharma America (MTPA) designed\n to identify biomarkers that could serve as quantifiable, biological and non-clinical measures of Edaravone's pharmacodynamic effect in ALS.\n To date, in the U.S., RADICAVA and RADICAVA ORS have been used to treat over 8,000 patients, with over 1.1 million days of therapy, and have been prescribed by nearly 2,000 HCPs\n \n ]\n \n .\n \n \n \n \n \n ALS, also\n known as Lou Gehrig's disease in the US and motor neuron disease (MND) in the UK, is a terminal\n disorder that attacks nerve cells that control voluntary muscle movements, like chewing, walking, and breathing, usually leading to\n death from ...